Keywords: Ablynx, Boehringer Ingelheim, Alzheimer's collaboration, Nanobodies, BIBW2992, Cancer, Head-and-neck, NSCLC
Ablynx gets 2 million-euro milestone from Boehringer Ingelheim Alzheimer’s collaboration; latter to unveil positive data on cancer drug
Article | 24 May 2010
German independent drug major Boehringer Ingelheim has selected a nanobody lead candidate for further development for the treatment of Alzheimer's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
